IDEAYA Biosciences (IDYA) Prepaid Assets (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Prepaid Assets of $18.3 million for Q1 2026, down 14.13% sequentially from $21.4 million in Q4 2025, and up 19.41% YoY from $15.4 million in Q1 2025.
IDEAYA Biosciences (IDYA) Prepaid Assets (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Prepaid Assets for 9 years, with the latest figure at $18.3 million in Q1 2026.
- Quarterly Prepaid Assets rose 19.41% year-over-year to $18.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.3 million (up 19.41% YoY) and the FY2025 annual result came in at $21.4 million, up 59.52% from the prior year.
- Prepaid Assets eased to $18.3 million in Q1 2026 per IDYA's latest filing, from $21.4 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $21.4 million in Q4 2025 and troughed at $2.8 million in Q1 2022.
- A 5-year average of $10.3 million and a median of $10.6 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets slipped 23.48% in 2022, then jumped 162.84% in 2024.
- Over 5 years, Prepaid Assets stood at $5.4 million in 2022, then jumped by 38.53% to $7.5 million in 2023, then jumped by 78.59% to $13.4 million in 2024, then jumped by 59.52% to $21.4 million in 2025, then dropped by 14.13% to $18.3 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $18.3 million, $21.4 million, and $15.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.65 Mn |
| Mar 31, 2026 | 18.35 Mn |
| Dec 31, 2025 | 21.37 Mn |
| Sep 30, 2025 | 15.76 Mn |
| Jun 30, 2025 | 15.86 Mn |
| Mar 31, 2025 | 15.36 Mn |
| Dec 31, 2024 | 13.39 Mn |
| Sep 30, 2024 | 12.17 Mn |
| Jun 30, 2024 | 11.52 Mn |
| Mar 31, 2024 | 10.57 Mn |
| Dec 31, 2023 | 7.50 Mn |
| Sep 30, 2023 | 6.73 Mn |
| Jun 30, 2023 | 7.91 Mn |
| Mar 31, 2023 | 4.02 Mn |
| Dec 31, 2022 | 5.41 Mn |
| Sep 30, 2022 | 3.74 Mn |
| Jun 30, 2022 | 3.28 Mn |
| Mar 31, 2022 | 2.75 Mn |
| Dec 31, 2021 | 3.12 Mn |
| Sep 30, 2021 | 3.39 Mn |